HYPR Hyperfine, Inc.
Electromedical & Electrotherapeutic Apparatus · Nasdaq · SEC CIK 1833769 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY80.0%
TTM net income YoY25.6%
TTM EPS YoY44.2%
Revenue 3-yr CAGR25.0%
Net income 3-yr CAGR—
Margins
Gross margin52.6%
Operating margin-167.6%
Net margin-156.4%
FCF margin-146.5%
EBITDA margin-162.0%
Returns
ROE-101.7%
ROA-60.0%
ROIC (approx.)-402.8%
Asset turnover0.38x
Leverage & solvency
Liabilities / assets45.1%
Debt / equity0.42x
Current ratio5.10x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.92x
Accruals ratio-4.5%
Payout ratio—
Capex / revenue1.9%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $13.56M | $12.89M | $11.03M | $6.81M | $1.50M |
| Cost of revenue | $6.81M | $7.00M | $6.28M | $5.91M | $2.66M |
| Gross profit | $6.75M | $5.89M | $4.76M | $907,000 | -$1.17M |
| R&D expense | $17.45M | $22.50M | $22.49M | $28.16M | $25.84M |
| SG&A expense | $16.25M | $17.49M | $20.28M | $32.41M | $27.50M |
| Operating income | -$37.09M | -$43.22M | -$48.12M | -$73.87M | -$64.87M |
| Pretax income | -$35.57M | -$40.72M | -$44.24M | -$73.16M | -$64.85M |
| Income tax | $0 | $0 | $0 | $0 | $0 |
| Net income | -$35.57M | -$40.72M | -$44.24M | -$44.24M | -$64.85M |
| EBITDA | -$35.99M | -$42.22M | -$47.06M | -$72.86M | -$64.14M |
| EPS (basic) | -0.43 | -0.56 | -0.62 | -1.04 | -17.57 |
| EPS (diluted) | -0.43 | -0.56 | -0.62 | -1.04 | -17.57 |
| Weighted avg. shares (diluted) | 81.80M | 72.41M | 71.32M | 70.45M | 3.69M |
| Balance sheet | |||||
| Cash & equivalents | $35.09M | $37.67M | $75.80M | $118.24M | $191.16M |
| Receivables | $5.25M | $5.96M | $3.19M | $2.10M | $553,000 |
| Inventory | $7.09M | $5.83M | $6.58M | $4.62M | $4.31M |
| Current assets | $50.91M | $53.71M | $88.91M | $128.66M | $197.49M |
| PP&E, net | $2.55M | $3.12M | $3.00M | $3.25M | $3.75M |
| Total assets | $55.26M | $58.90M | $94.20M | $134.05M | $202.47M |
| Current liabilities | $11.73M | $8.73M | $8.77M | $8.80M | $15.74M |
| Long-term debt | $0 | — | — | — | — |
| Total debt | $0 | — | — | — | — |
| Total liabilities | $14.26M | $9.86M | $9.80M | $10.33M | $16.25M |
| Shareholders' equity | $41.01M | $49.04M | $84.40M | $123.72M | $186.23M |
| Net debt | -$35.09M | — | — | — | — |
| Cash flow statement | |||||
| Operating cash flow | -$27.95M | -$38.77M | -$41.81M | -$72.34M | -$47.18M |
| Capital expenditure | $1.19M | $383,000 | $804,000 | $585,000 | $2.71M |
| Free cash flow | -$29.13M | -$39.15M | -$42.61M | -$72.92M | -$49.89M |
| Investing cash flow | -$1.19M | -$383,000 | -$804,000 | -$585,000 | -$2.71M |
| Financing cash flow | $27.50M | $1.02M | $174,000 | $7,000 | $176.77M |
| Depreciation & amortization | $1.09M | $1.01M | $1.05M | $1.01M | $726,000 |
| Stock-based compensation | $2.80M | $4.36M | $4.74M | $10.65M | $6.90M |
Free plan shows the latest 5 periods; Pro shows all 6 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.